Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AQUESTIVE THERAPEUTICS, INC.

(AQST)
  Report
Real-time Estimate Cboe BZX  -  09:38 2022-10-07 am EDT
1.085 USD   -2.25%
09/29Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant (diazepam) Buccal Film for European and MENA Markets
AQ
09/28Aquestive Therapeutics Enters License, Supply Agreement with Pharmanovia for Libervant in Europe, MENA
MT
09/28Aquestive Therapeutics, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AQUESTIVE THERAPEUTICS, INC. : Other Events (form 8-K)

04/24/2020 | 04:03pm EDT

Item 8.01 Other Events

Aquestive Therapeutics, Inc. (the "Company") was granted a $4.8 million loan on April 17, 2020 under the Paycheck Protection Program (the "PPP"), Division A, Title I of the United States CARES Act, which was enacted on March 27, 2020. Based upon guidance issued yesterday by the Federal Government including a presumption that no publicly traded companies are eligible for a PPP loan, the Company intends to return the PPP loan proceeds within the time period imposed under these new guidelines, subject to any additional guidance that may be issued by the Federal Government on eligibility criteria for public companies who have already been granted PPP loans.

© Edgar Online, source Glimpses

All news about AQUESTIVE THERAPEUTICS, INC.
09/29Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Liberva..
AQ
09/28Aquestive Therapeutics Enters License, Supply Agreement with Pharmanovia for Libervant ..
MT
09/28Aquestive Therapeutics, Inc. : Entry into a Material Definitive Agreement, Other Events, F..
AQ
09/28Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Comp..
AQ
09/28Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Liberva..
GL
09/28Aquestive Therapeutics, Inc. Enters License and Supply Agreement with Pharmanovia for L..
CI
09/27Aquestive Therapeutics, Inc. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
09/27Wall Street Set to Open Higher Ahead of Consumer Confidence, New Home Sales Reports
MT
09/27Aquestive Therapeutics Says AQST-109 Sublingual Epinephrine Shows Faster Concentration ..
MT
09/27US Futures, Oil Climb Higher
MT
More news
Analyst Recommendations on AQUESTIVE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 47,3 M - -
Net income 2022 -60,6 M - -
Net Debt 2022 40,3 M - -
P/E ratio 2022 -0,94x
Yield 2022 -
Capitalization 59,2 M 59,2 M -
EV / Sales 2022 2,10x
EV / Sales 2023 3,44x
Nbr of Employees 157
Free-Float 97,7%
Chart AQUESTIVE THERAPEUTICS, INC.
Duration : Period :
Aquestive Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AQUESTIVE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,11 $
Average target price 6,36 $
Spread / Average Target 473%
EPS Revisions
Managers and Directors
Daniel Barber President, Chief Executive Officer & Director
A. Ernest Toth Chief Financial Officer & Senior Vice President
Santo J. Costa Chairman
A. Mark Schobel Chief Technology & Innovation Officer
Peter Boyd SVP-Business Process & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
AQUESTIVE THERAPEUTICS, INC.-71.47%59
JOHNSON & JOHNSON-5.35%425 691
ELI LILLY AND COMPANY20.11%316 361
ROCHE HOLDING AG-14.13%271 357
ABBVIE INC.3.61%248 046
PFIZER, INC.-25.28%241 836